Country: United States
Language: English
Source: NLM (National Library of Medicine)
FONDAPARINUX SODIUM (UNII: X0Q6N9USOZ) (FONDAPARINUX - UNII:J177FOW5JL)
Physicians Total Care, Inc.
FONDAPARINUX SODIUM
FONDAPARINUX SODIUM 5 mg in 0.4 mL
SUBCUTANEOUS
PRESCRIPTION DRUG
ARIXTRA® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. ARIXTRA is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. ARIXTRA is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. ARIXTRA is contraindicated in the following conditions: - Severe renal impairment (creatinine clearance [CrCl] <30 mL/min). [See Warnings and Precautions (5.2) and Use in Specific Populations (8.6).] - Active major bleeding. - Bacterial endocarditis. - Thrombocytopenia associated with a positive in vitro test for anti-platelet antib
ARIXTRA Injection is available in the following strengths and package sizes: 5 mg ARIXTRA in 0.4 mL single-dose prefilled syringe, affixed with a 27-gauge x ½-inch needle and an automatic needle protection system with white plunger rod. 7.5 mg ARIXTRA in 0.6 mL single-dose prefilled syringe, affixed with a 27-gauge x ½-inch needle and an automatic needle protection system with white plunger rod. Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F).
New Drug Application
ARIXTRA - FONDAPARINUX SODIUM INJECTION, SOLUTION PHYSICIANS TOTAL CARE, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ARIXTRA SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ARIXTRA. ARIXTRA (FONDAPARINUX SODIUM) SOLUTION FOR SUBCUTANEOUS INJECTION INITIAL U.S. APPROVAL: 2001 WARNING: SPINAL/EPIDURAL HEMATOMAS EPIDURAL OR SPINAL HEMATOMAS MAY OCCUR IN PATIENTS WHO ARE ANTICOAGULATED WITH LOW MOLECULAR WEIGHT HEPARINS (LMWH), HEPARINOIDS, OR FONDAPARINUX SODIUM AND ARE RECEIVING NEURAXIAL ANESTHESIA OR UNDERGOING SPINAL PUNCTURE. THESE HEMATOMAS MAY RESULT IN LONG-TERM OR PERMANENT PARALYSIS. CONSIDER THESE RISKS WHEN SCHEDULING PATIENTS FOR SPINAL PROCEDURES. FACTORS THAT CAN INCREASE THE RISK OF DEVELOPING EPIDURAL OR SPINAL HEMATOMAS IN THESE PATIENTS INCLUDE: ● USE OF INDWELLING EPIDURAL CATHETERS ● CONCOMITANT USE OF OTHER DRUGS THAT AFFECT HEMOSTASIS, SUCH AS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), PLATELET INHIBITORS, OR OTHER ANTICOAGULANTS ● A HISTORY OF TRAUMATIC OR REPEATED EPIDURAL OR SPINAL PUNCTURE ● A HISTORY OF SPINAL DEFORMITY OR SPINAL SURGERY MONITOR PATIENTS FREQUENTLY FOR SIGNS AND SYMPTOMS OF NEUROLOGIC IMPAIRMENT. IF NEUROLOGIC COMPROMISE IS NOTED, URGENT TREATMENT IS NECESSARY. CONSIDER THE BENEFIT AND RISKS BEFORE NEURAXIAL INTERVENTION IN PATIENTS ANTICOAGULATED OR TO BE ANTICOAGULATED FOR THROMBOPROPHYLAXIS._ [SEE WARNINGS AND PRECAUTIONS (5.5) AND DRUG INTERACTIONS (7).]_ INDICATIONS AND USAGE ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for: (1) Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. (1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. (1.2, 1.3) DOSAGE AND ADMINISTRATION Prophylaxis of deep vein thrombosis: ARIXTRA 2.5 mg subcutaneously once daily after hemostasis has Read the complete document